EPHA2 and neoplasm: Ephrin ligand mimicking peptides [30–32] engineered into multivalent structures have been shown to be potent stimulators of canonical EphA2 activity, with subsequent internalisation and degradation of the receptor, preventing non-canonical EphA2 activity and thereby suppressing tumour progression.